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Nathan and Pawlik have written an important
commentary regarding secondary analyses of large
population-based data sets
1 for this issue of the An-
nals of Surgical Oncology. The commentary high-
lights not only some of the important issues that
investigators need to address when performing such
studies, but also some of the issues that the reder
needs to understand when evaluating these types of
studies. Each of the issues raised by the authors is
important and could be the focus of a detailed dis-
sertation; we would like to build on their commentary
and discuss ﬁve items/ideas as the ﬁeld moves for-
ward.
1. Investigators: As a starting point, the important
bottom-line message of the commentary is that
investigators should be aware of the inherent
limitations of large population-based data set
analyses. While it is true that many of these data
sets are relatively simple to obtain and inexpen-
sive—coupled with the fact that performing anal-
yses is becoming ‘‘easier’’ with the availability of
menu-driven statistical software packages, it
remains essential that rigorous, methodologically
sound studies are performed. Similar to surgery, a
little knowledge can be a dangerous thing—and as
a start for performing these analyses, more than a
rudimentary knowledge of statistics and epidemi-
ology is needed. Working with investigators/
collaborators experienced and trained in these
areas is prudent.
2. Publishing Standards: It may be useful to have
guidelines or standards for these types of studies
when publishing. This would include, at the very
least, a thorough discussion of the limitations and
how they might affect the ﬁndings and implica-
tions of the study. Going further, it may be an aim
for the future to have a set of criteria developed
for the publication of large population-based data
sets, similar to the CONSORT criteria used for
reporting randomized controlled trials.
2
3. Peer Review: Along the same lines as providing
criteria for authors who publish such studies, help
for the reviewers performing peer assessments of
submitted manuscripts may also be beneﬁcial.
More speciﬁcally, with the increasing number of
manuscripts using secondary data analyses being
submitted to journals such as the Annals of
Surgical Oncology, standards, criteria, and infor-
mation about the common data sets may help to
improve consistent and rigorous peer review. At
the American College of Surgeons, the Committee
on Trauma has its registry data set, the National
Trauma Data Bank. Those in charge of the
database have developed a ‘‘guideline/description’’
that not only explains the data set and its content,
but also highlights the known and potential
limitations to help peer review studies for journals
using this database. The same type of paper is
currently being developed for the National Cancer
Data Base. Similar papers that are speciﬁc to the
common data sets may be developed and made
available to reviewers. Additionally, a general
‘‘secondary data analysis’’ guideline could be
Received September 15, 2007; accepted September 17, 2007;
published online: December 11, 2007.
Address correspondence and reprint requests to: Clifford Y. Ko,
MD; E-mail: cko@mednet.ucla.edu
Published by Springer Science+Business Media, LLC  2008 The Society of
Surgical Oncology, Inc.
Annals of Surgical Oncology 15(2):395–396
DOI: 10.1245/s10434-007-9657-4
395developed that highlights many of the points
addressed in the commentary by Nathan and
Pawlik. Again, as these submissions are likely to
increase, some type of standard will probably help
to improve peer review and the consequent quality
of published studies.
4. Quality and Appropriateness of Care: Currently in
our health-care system, we are being increasingly
regulated by performance measurement. In this
regard, the population-based data sets are poten-
tially very helpful and robust tools for examining
and identifying problematic areas of quality of
care. They allow us to obtain, for example, rates of
procedures, concordance to various performance
measures, and rates of outcomes, among other
things. Concomitantly, these population-based
data sets also allow us to describe and study some
of the factors associated with variation of these
metrics/rates, such as underuse of surgery, che-
motherapy, etc. While the statistics of such reports
may be simple, given the studies may be solely
descriptive, it is essential that the investigators
understand the quality and validity of the data
that are being used. For example, it is important
to recognize that underuse of a particular therapy
can be actual underuse, or it may simply be
undercoding of the therapy.
5. Randomized Controlled Trials vs Observational
Studies: Observational treatment studies using
large population-based data have often been
touted as being too biased to contribute substan-
tially to our knowledge base—but the jury may
still be out in this regard. Certainly the random-
ized controlled trial is considered the best study
design for studying treatment effects; however,
these trials do have their own limitations such as
generalizability, they are often difﬁcult to perform,
and they are expensive. With regard to the
performance of other study designs lower in the
hierarchy, it is interesting to recognize that well-
performed observational studies may be extremely
useful in the literature. In fact, studies have found
that when observational trials and randomized
controlled trials on the same topic are compared,
there is little evidence that the results of observa-
tional trials are different from those of random-
ized controlled trials. In other words, they have
been found to identify the same qualitative result
as well as virtually the same magnitude of treat-
ment effect.
3,4 Further study to examine these
same issues in surgical oncology is warranted.
In conclusion, data are key to investigation.
Incumbent on moving forward is high-quality data
and high-quality analysis while recognizing the limi-
tations of both. Nathan and Pawlik highlight a
number of important issues one needs to address
while working with such data sets, and similar studies
will only likely increase. Given the advances in tech-
nology and growing data availability, data will be
increasingly merged—this includes potentially com-
bining cancer registries, claims data, pharmacy ﬁles,
laboratory tests, inpatient and outpatient data, phy-
sician information, etc. Even adding in some primary
clinical data to these data sets is occurring. As a re-
sult, a potentially better and more complete picture
may be obtained when performing such studies. As
all of this happens, an appropriate understanding of
the data and techniques to analyze them is para-
mount. As highlighted in the commentary, the
understanding of issues relevant to study design,
statistics, and epidemiology, among other topics, is
required to responsibly perform such work.
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